11th March 2022Elasmogen
11th March 2022Cazoo
11th March 20223-SIXTY
11th March 2022AutoLab Car Services
11th March 2022Simfoni
11th March 2022GTS Flexible Materials
22nd February 2022Nova Pangaea Technologies
15th March 2021Shawbrook Bank
15th March 2021Wilton and Bain Group Limited
15th March 2021Unily
15th March 2021Transcend Packaging
15th March 2021The Technology Group
15th March 2021One Utility Bill
15th March 2021Laird London
15th March 2021Hannah Woodgates Hair Design
15th March 2021Alexander Technologies
BBI Programme: Regional Angels
Delivery partner: Deepbridge Capital
Part of a cluster of biotech companies in Aberdeen, Elasmogen uses its bespoke technology platform to isolate innovative drugs for treating cancers and auto-immune diseases.
With a strong foundation of intellectual property and a healthy pipeline of new programmes, Elasmogen had progressed several innovative drugs to the late pre-clinical stage. Finance is vital at this early research and development stage.
Funding from Regional Angels Programme delivery partner Deepbridge has added value to the company’s platform, processes and products – and helped to retain its talented team. Elasmogen is now in a position to consider its next major milestone: entering clinical trials.
“ It has transformed our ability to demonstrate the advantages of our technology over the competition.”
Caroline Barelle, CEO